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Abstract
Purpose Attrition and subsequent missing data pose a challenge in longitudinal research in oncology. This study examined
factors associated with attrition in the PROFILES registry, and its impact on observed health-related quality of life (HRQOL)
estimates.
Methods Sociodemographic, clinical, and HRQOL data were collected annually from a cohort of 2625 colorectal cancer
survivors between 2010 and 2015. Participant characteristics according to time of dropout were compared using analysis of
variance and chi-square tests. Predictors of attrition were examined in logistic regression analysis. Multilevel linear mixedmodels
were constructed to investigate associations between attrition and HRQOL over time.
Results Participants who dropped out were more likely to be female (OR = 1.23, CI = 1.02–1.47), older (OR = 1.20, CI = 1.09–
1.33), less educated (OR = 1.64, CI = 1.30–2.11), and to have depressive symptoms (OR = 1.84, CI = 1.39–2.44) than full
responders, and less likely to have high socioeconomic status (OR = 0.74, CI = 0.61–0.94). Participants who dropped out earlier
reported significantly worse HRQOL, functioning, and psychosocial symptoms, which declined at a steeper rate over time, than
full responders.
Conclusions Cancer survivors’ HRQOL may be overestimated in longitudinal research due to attrition of the most unwell
participants.
Implications for Cancer Survivors Cancer survivors with the poorest health are at risk of dropping out of PROFILES and possibly
withdrawing from other activities. Optimizing participation in PROFILES—a potential mechanism for providing information
and access to support—is an avenue for keeping this group engaged.
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Background
Patient-reported outcomes (PRO) are patients’ self-reports
about the impacts of a health condition on functioning, symp-
toms, and health-related quality of life (HRQOL) as well as
experiences of treatment and care. PRO data can support the
provision of patient-centred care by informing decision-
making at the individual level, driving quality improvement
at a system level, and determining factors that influence pa-
tient outcomes on a population level [1]. Missing data poses a
challenge for PRO research, particularly as it relates to attri-
tion (i.e. when a participant drops out and is never observed
again) [2]. Despite its implications for data quality, analysis,
and interpretation, the mechanisms of attrition in population-
based PRO research are not well understood [2].
The Netherlands PROFILES registry is a unique system for
comprehensive population-level PRO monitoring, which seeks
to understand the burden and trajectory of outcomes
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experienced by cancer survivors post-treatment [3]. Since 2008,
PROFILES has collected longitudinal PRO data from over
20,000 cancer survivors, with participation rates similar to or
higher than comparable observational studies [4–6]. Through
population-level reach, PROFILES provides a novel way to
surmount some of the challenges associated with recruiting
and retaining post-treatment cancer survivors in longitudinal
clinical research, allowing greater external validity and gener-
alizability [7]. Other advantages include data linkage with the
Netherlands Cancer Registry (NCR), which records clinical and
sociodemographic information about all individuals newly di-
agnosed with cancer in the Netherlands. However, this type of
observational research requires dedicated participants who are
able and willing to participate long term.
Attrition is a ubiquitous problem in longitudinal research [8].
Because it may be selective (e.g. due to declining health or
death), attrition can bias the representativeness of the sample
[8]. Factors associated with attrition in oncology trials include
death, symptom burden, illness, advanced disease, increased
age, low socioeconomic status, and being from a minority
group [9–11]. A cross-sectional study comparing invited cancer
survivors who did not participate in PROFILESwith those who
did found that non-participants had lower survival and lower
estimated HRQOL than participants [12], but it is not known
whether similar differences exist between those who participate
long term and those who drop out. Furthermore, there have
been few attempts to document the pattern of and reasons for
attrition in population-based cohort studies of cancer survivors
generally [2, 13]. Understanding how, why, and who is likely to
participate in this context has important implications for
interpreting findings from PROFILES, estimating sample sizes,
and improving participant retention in future studies.
This study aimed to determine the rate of and factors asso-
ciated with attrition among colorectal cancer survivors partici-
pating in the largest cohort of the PROFILES registry, and to
assess the impact of attrition on observed HRQOL outcomes
over time. This population provides a useful case to examine
the challenges of conducting longitudinal PRO research; colo-
rectal cancer is the third most common cancer in Europe and
the world, and the 5-year survival rate in the Netherlands is
65% [14]. The study objectives were to (1) examine
sociodemographic and clinical factors that influence the likeli-
hood of attrition in PROFILES, and (2) investigate differences
in longitudinal HRQOL, anxiety, and depressive symptoms
according to time of dropout.
Methods
Design and setting
This study used data from PROFILES, which collects PRO
from cancer survivors within a sampling frame of the NCR.
The first wave commenced in December 2010 (T1) and par-
ticipants received follow-up questionnaires in 2011 (T2),
2012, (T3), 2013 (T4), and 2014 (T5). Figure 1 presents an
overview of study participation.
Data collection
The data collection process has been described in detail else-
where [3, 15]. In brief, eligible participants were informed
about PROFILES via a letter from their (ex-)attending special-
ist, accompanied by a consent form and questionnaire or a
secured link to an online form and questionnaire, with an
option to request a paper version. If no response was received
after 2 months, a reminder letter and paper questionnaire was
sent. Participants who did not complete a questionnaire were
classified as non-responders for that wave but could still be
invited to subsequent waves.
Study population
Eligible participants were individuals diagnosed with colon or
rectal cancer between January 2000 and June 2009 as regis-
tered in the NCR. Individuals unable to complete a question-
naire according to their (ex-)attending specialist (i.e. cogni-
tively impaired, too ill, or non-native speaker) or who had
unverifiable addresses were excluded. Address checks were
performed at each wave to verify whether the registered ad-
dress corresponded with national zip code registration.
Study measures
PRO were assessed at T1, T2, T3, and T5. The T4 question-
naire contained measures unrelated to the study outcomes re-
ported here and was therefore considered in terms of response
only. Dates of invitation and response were recorded at each
wave.
Sociodemographic characteristics
Sociodemographic data included sex, birth date, and socioeco-
nomic status (SES). SES was determined based on residential
postcode and aggregated fiscal data [16]. Marital status and
education were assessed in the questionnaire.
Clinical characteristics
Clinical data included date of diagnosis, tumour type, stage,
and primary treatments. Tumour type and stage were classi-
fied according to the third International Classification of
Diseases for Oncology (ICDO-3) [17] and TNM, respectively
[18]. Comorbidity was assessed with the adapted Self-
Administered Comorbidity Questionnaire [19]. Mortality data
J Cancer Surviv (2019) 13:829–839830
6446 colorectal cancer (CRC) patients diagnosed between January 
2000 and June 2009, aged ≤85 years were selected from the NCR
(Ex-)attending specialists from 10 hospitals were invited for study 
participation and to allow access to 4227 CRC patients
The status of 4058 CRC patients were checked against ECR and 
hospital records
3585 CRC patients were eligible for participation and received a 
questionnaire for Wave 1
2625 (73%) CRC patients completed the questionnaire from Wave 1
2219 CRC patients who had been previously selected for a study 
were excluded
1 participating hospital excluded 169 rectal cancer patients due to 
other ongoing research
327 CRC patients died prior to the study start, 63 CRC patients 
were demented or terminally ill and 83 CRC patients with stage 
0/carcinoma in situ were excluded
619 (17%) CRC patients did not return a questionnaire
341 (10%) had unverifiable addresses
75 participants died 
470 elected to discontinue participation
102 did not a return consent form
3 were too ill or cognitively impaired
3 were not selected for further participation 
9 non-responders from Wave 1 were selected for participation in Wave 2
1981 CRC patients were eligible and invited for Wave 2
333 (17%) refused or did not return the questionnaire
5 (0%) had unverifiable addresses
1643 (83%) participants completed the questionnaire from Wave 2
56 participants died
129 elected to discontinue participation 
12 did not return a consent form 
9 were too ill or cognitively impaired
1 was excluded due to recurrent disease
1774 CRC patients were eligible and invited for Wave 3
308 (17%) CRC patients actively refused or did not return the questionnaire
8 (0%) CRC patients had unverifiable addresses
1458 (82%) CRC patients completed the questionnaire from Wave 3
38 participants died and 112 discontinued participation
1624 CRC patients were invited for Wave 4
301 (19%) refused or did not return the questionnaire
7 (0%) had unverifiable addresses
1316 (81%) participants completed the questionnaire from Wave 4
15 participants died and 62 discontinued participation
1547 CRC patients were invited for Wave 5
301 (19%) CRC patients refused or did not return the questionnaire
0 (0%) CRC patients had unverifiable addresses





Fig. 1 Flow chart of study participation
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were obtained from the Dutch municipal personal records da-
tabase and were last verified on 31 January 2018.
Patient-reported outcome measures
The EORTC QLQ-C30 (version 3.0) was used to assess
HRQOL [20]. The questionnaire contains scales for physical,
role, social, emotional, and cognitive functioning; a global
HRQOL scale; and symptom scales for fatigue, pain, and
nausea/vomiting [20]. Items are rated on a four-point scale
ranging from 1 to 4. All scores were linearly transformed to
a scale of 1 to 100 as per the EORTC guidelines [21]. A
summary score was calculated from the mean of 13 of the
15 QLQ-C30 scales [22].
Depressive and anxiety symptoms were assessed with the
Hospital Anxiety and Depression Scale (HADS), which con-
tains two 7-item subscales for each construct [23]. Items are
scored on a four-point scale ranging from 0 to 3, with higher
scores indicated higher symptom prevalence. Sum scores
ranging from 0 to 21 were calculated for both subscales, and
a recommended cut-off score of 8 was used to define the
presence of anxiety disorders and depressive symptoms [24].
Statistical analysis
Participants were stratified into groups based on their last
completed questionnaire: dropped out after T1, dropped out
after T2, dropped out after T3/T4 (combined due to aforemen-
tioned difference in the T4 assessment), and full responders
(participants who completed the final assessment, regardless
of intermittently missing assessments).
Sociodemographic and clinical group characteristics were
compared using analysis of variance (ANOVA) and chi-
square tests where appropriate. Post hoc comparisons were
made using Tukey’s method. To investigate predictors of at-
trition, multivariable logistic regression analysis was per-
formed with full response vs. dropout as outcomes, excluding
participants with attrition due to death. Factors included as
potential predictors were sex, age, partner, SES, education,
comorbidity, treatment, QLQ-C30 functioning subscales, de-
pressive symptoms, and anxiety.
Multilevel linear mixed models were constructed to inves-
tigate associations between study participation and PRO,
allowing adjustment for interdependency of repeated observa-
tions within patients and correction for missing data at random
[25]. This technique uses data efficiently by including incom-
plete cases in analysis, limiting bias, and preserving statistical
power [26]. Time was analysed as a categorical predictor with
four levels (T1, T2, T3, T5). Sociodemographic and clinical
variables were analysed as time-invariant predictors using T1
characteristics. Overall effects were assessed comparing out-
comes for full responders with participants who dropped out
stratified by time of dropout. The final models were adjusted
for time, age, sex, SES, education, marital status, comorbidity,
disease stage, and treatment. Graphs present unadjusted
means by group over time, with p values indicating differ-
ences between group means and slopes after adjustment. To
highlight these differences, graphs are presented on a scale
from 60 to 90. Sensitivity analyses excluding participants
who died were performed.
Statistical tests were two-sided and considered significant
if p < 0.05. Analyses were performed in SAS version 9.4.
Clinically relevant differences were determined using
evidence-based guidelines for interpretation of the QLQ-C30
between groups, which provide estimates for trivial, small,
medium, and large mean differences [27].
Results
Attrition rate
The survey was completed by 73% of invited participants at
T1 (n = 2625). Of those that were eligible and invited at each
wave, the proportion of participants who completed that wave
was 83% at T2 (n = 1643), 82% at T3 (n = 1458), 81% at T4
(n = 1316), and 81% at T5 (n = 1216). Table 1 shows the
number of participants who dropped out after each assess-
ment. Total attrition was 53% (n = 1388). In most cases the
reason was unknown (n = 1174, 83%). Death accounted for
13% of attrition overall (n = 184), 1% of participants had un-
verifiable addresses during follow-up (n = 20), and < 1%were
unable to continue participation due to illness or cognitive
impairment (n = 12).
Sociodemographic and clinical characteristics
It has been previously reported that participants at T1 had a
longer time since diagnosis and were significantly younger
andmore oftenmale, diagnosedwith stage I disease, and treated
with radiotherapy than non-participants at T1 [28]. Full re-
sponders were more often male, less than 70 years old,
partnered, university educated, diagnosed at stage I, and treated
with radiotherapy than participants who dropped out or non-
participants (Table 1). They were also more likely to have high
SES and one comorbid condition, but less likely to have three
or more comorbid conditions, than participants who dropped
out or non-participants (Table 1). No group differences were
found for years since diagnosis or receiving chemotherapy.
Predictors of attrition
Predictors of attrition in multivariable logistic regression were
being female (OR = 1.23, CI = 1.02–1.47), older age (OR =
1.20, CI = 1.09–1.33), low education (OR = 1.64, CI = 1.30–
2.11), presence of depressive symptoms (OR = 1.84, CI =
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Male 458 (48%) 432 (50%) 119 (54%) 177 (57%) 723 (58%)
Female 493 (52%) 424 (50%) 100 (46%) 136 (43%) 523 (42%)
Age (years), M (SD) 70.9 (11.2) 71.4 (9.3) 70.5 (9.6) 69.3 (9.8) 67.9 (9.3) < 0.001
Age (years) < 0.001
< 59 144 (15%) 105 (12%) 33 (15%) 48 (15%) 225 (18%)
60–69 230 (24%) 209 (24%) 60 (27%) 108 (35%) 473 (38%)
70–79 355 (37%) 383 (45%) 88 (40%) 112 (36%) 440 (35%)
80< 222 (23%) 159 (19%) 38 (17%) 45 (14%) 108 (9%)
Partner < 0.001
Yes – 600 (71%) 166 (78%) 239 (77%) 979 (79%)
SES < 0.001
Low 275 (29%) 196 (23%) 45 (21%) 68 (22%) 217 (17%)
Medium 385 (40%) 360 (42%) 95 (43%) 136 (44%) 471 (38%)
High 245 (26%) 275 (32%) 71 (32%) 94 (30%) 506 (41%)
Unknown/care institution 46 (5%) 25 (3%) 8 (4%) 15 (5%) 52 (4%)
Education < 0.001
Low – 230 (27%) 55 (25%) 63 (20%) 172 (14%)
Medium – 489 (57%) 124 (57%) 187 (60%) 768 (62%)
High – 117 (14%) 31 (14%) 62 (20%) 298 (24%)
Unknown – 20 (2%) 9 (4%) 1 (0%) 8 (1%)
Clinical Clinical
Years since diagnosis, M (SD) 5.3 (2.9) 5.3 (2.8) 5.0 (2.8) 5.1 (2.8) 5.1 (2.8) 0.52
Stage 0.001
I 241 (25%) 249 (29%) 58 (26%) 87 (28%) 392 (31%)
II 388 (41%) 326 (38%) 78 (36%) 115 (37%) 432 (35%)
III 244 (26%) 209 (24%) 65 (30%) 89 (28%) 359 (29%)
IV 50 (5%) 56 (7%) 14 (6%) 12 (4%) 31 (2%)
Unknown 28 (3%) 16 (2%) 4 (2%) 10 (3%) 32 (3%)
Chemotherapy 0.76
Yes 251 (26%) 241 (28%) 68 (31%) 90 (29%) 373 (30%)
Radiotherapy 0.02
Yes 231 (24%) 232 (27%) 62 (28%) 108 (35%) 406 (33%)
Surgery < 0.01
Yes 929 (98%) 839 (98%) 217 (99%) 312 (100%) 1240 (100%)
Comorbidities < 0.01
0 – 183 (21%) 45 (21%) 83 (27%) 303 (24%)
1 – 201 (23%) 52 (24%) 71 (23%) 385 (31%)
2 – 170 (20%) 48 (22%) 71 (23%) 266 (21%)
3 or more – 202 (24%) 60 (27%) 71 (23%) 241 (19%)
Unknown – 100 (12%) 14 (6%) 17 (5%) 51 (4%)
Died before next invitation 72 (28%) 75 (13%) 56 (31%) 53 (20%) – < 0.001
Note: p values report overall ANOVA for normally distributed continuous variables, chi-square tests for categorical variables, and Wilcoxon tests for
non-normally distributed continuous variables.Means (M) with standard deviations (SD) were used to describe normally distributed continuous variables
and frequencies with percentages were used to describe categorical variables
a Invited cancer survivors who declined to participate or had unverifiable addresses
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1.39–2.44), and havingmissing education or comorbidity data
(OR = 5.51, CI = 1.20–25.16; OR = 2.21, CI = 1.42–3.44)
(Table 2). High SES was inversely associated with attrition
(OR = 0.77, CI = 0.62–0.94) (Table 2).
Study participation and HRQOL
ANOVA tests showed significant differences between the
dropout groups on all functioning and symptom scales at T1
(all p values < 0.05; see Table S1). Pairwise comparisons in-
dicated that participants who dropped out after T1 or T2 had
statistically significantly lower baseline summary score, phys-
ical functioning, and role functioning and higher fatigue than
participants who completed three or more assessments, and
these differences were clinically relevant (Table S1). Full re-
sponders had significantly higher global HRQOL and emo-
tional functioning, and less nausea than participants who
dropped out after T1. They also had significantly lower anx-
iety symptoms than participants who dropped out after T2,
and depressive symptoms than all dropout groups (Table S1).
In multilevel linear mixed models adjusted for time, age,
sex, SES, education, marital status, comorbidity, disease stage,
and treatment, at baseline full responders had significantly
higher global HRQOL, physical functioning, role functioning,
social functioning, and summary score (Fig. 2a–e), and less
fatigue (Fig. 2h) than participants who dropped out after T1 or
T2. They also reported significantly higher emotional func-
tioning and cognitive functioning and less anxiety symptoms
than participants who dropped out after T1, and less depres-
sive symptoms than participants who dropped out at T1, T2,
or T3/T4 (Fig. 2f, g; Fig. 2i, j). There were no significant
group differences for nausea or pain (not shown). The differ-
ence between the adjusted means of full responders and par-
ticipants who dropped out after T1 was of small clinical im-
portance for global HRQOL, physical functioning, role func-
tioning, and fatigue [27].
Full responders had a more stable PRO trajectory than par-
ticipants who dropped out. Over time, participants who
dropped out after T2 or T3/T4 showed a steeper decline in
global HRQOL and physical functioning and a steeper in-
crease in depression than full responders (all p values <
0.05; see Fig. 2b, c; Fig. 2j). Compared with full responders,
participants who dropped out at T3/T4 also showed steeper
declines in social and emotional functioning and the summary
score (all p values < 0.05; see Fig. 2a; Fig. 2e, f).
Sensitivity analyses excluding patients with attrition
due to death showed no significant differences in PRO
trajectory between full responders and participants who
dropped out at T2 or T3/T4. However, there remained
significant baseline differences between full responders
and participants who dropped out after T1 on all PRO
except for anxiety and social functioning.
Discussion
Compared with full responders, colorectal cancer survivors
who dropped out of PROFILES were more likely to be wom-
en, older, less educated, and to have depressive symptoms,
and less likely to have high SES. Full responders reported
better HRQOL at each assessment than participants who
dropped out, with poorer outcomes generally indicating earlier
dropout. Participants who dropped out after the second, third,
or fourth wave showed a steeper decline in global HRQOL
and physical functioning and a steeper increase in depressive
symptoms than full responders. Participants who dropped out
after the third or fourth wave also showed a steeper decline in
social functioning, emotional functioning, and the summary
score. Sensitivity analyses suggested this trend was driven by
mortality, although first wave dropouts still reported
worse initial HRQOL than full responders, unrelated to
mortality.
Non-response and attrition have consistently been associ-
ated with sociodemographic factors including low education
and SES in longitudinal studies with cancer patients [4, 11]
and general populations [29–31] and the link between low
SES and poor health—another predictor of attrition—is well
established [30–33]. Cancer patients with low SES are often
underrepresented in clinical trials [4, 34, 35], in some in-
stances even after accounting for education and comorbidity
[35]. The higher rate of dropout among women in our sample
was not unexpected, given that men are more likely to partic-
ipate in PROFILES than women [12]. This is contrary to
evidence that participation in population-based research is
generally higher among women than men [36, 37] although
studies have also observed the opposite [38, 39]. The results
also differ from numerous studies with cancer populations that
did not find associations between sex and participation [4–6]
or attrition [9–11]. An explanation may be provided by grow-
ing evidence for sex-based differences in response to antican-
cer treatments, showing that women experience higher inci-
dence of toxicity and adverse reactions than men [40, 41]. It is
possible that women in our sample experienced more
treatment-related symptoms than men, which made them
more likely to discontinue participation. Further research is
needed to give insight into sex differences in cancer and the
resulting impact on research participation and other
behaviours.
Associations between older age and attrition have been
reported in clinical cancer trials [34], and linked with cogni-
tive impairment and poorer health [42]. Contrary to evidence
demonstrating a link between higher prevalence of health-
related problems and attrition, having a higher number of co-
morbid conditions was not associated with dropout [31, 38].
Cancer stage did not predict likelihood of full response, al-
though other studies have found that patients with more ad-
vanced cancer are more likely to drop out [11].
J Cancer Surviv (2019) 13:829–839834
Table 2 Factors associated with dropout during follow-up, multivariable logistic regression








Male 723 (58%) 611 (51%) 1.00 (ref)
Female 523 (42%) 593 (49%) 1.23* 1.02–1.47
Age, M (SD) 67.90 (9.31) 70.61 (9.63) 1.20** 1.09–1.33
Partner
Yes 979 (80%) 863 (73%) 1.08 0.87–1.34
SES
Low 217 (17%) 270 (22%) 0.99 0.76–1.23
Medium 471 (38%) 514 (43%) 1.00 (ref)
High 506 (41%) 381 (32%) 0.74** 0.61–0.94
Unknown/care
institution
52 (4%) 41 (3%) 0.74 0.46–1.19
Education
Low 172 (14%) 304 (25%) 1.64** 1.30–2.11
Medium 768 (62%) 692 (57%) 1.00 (ref)
High 298 (24%) 181 (15%) 0.87 0.69–1.09
Unknown 8 (1%) 27 (2%) 5.51* 1.20–25.16
Stage
I 392 (32%) 356 (30%) 0.86 0.69–1.07
II 432 (36%) 469 (39%) 1.00 (ref)
III 359 (30%) 310 (26%) 0.82 0.63–1.06
IV 31 (3%) 40 (3%) 1.18 0.66–2.09
Unknown 32 (3%) 29 (2%) 0.98 0.56–1.70
Treatment
Chemotherapy 373 (30%) 333 (28%) 1.06 0.83–1.36
Radiotherapy 406 (33%) 336 (28%) 0.89 0.74–1.08
Surgery 1240 (100%) 1194 (99%) 0.76 0.25–2.32
Comorbidities
0 303 (24%) 273 (23%) 1.29 0.98–1.67
1 385 (31%) 288 (24%) 0.90 0.71–1.16
2 266 (21%) 251 (21%) 1.00 (ref)
3 or more 241 (19%) 276 (23%) 0.96 0.73–1.25
Unknown 51 (4%) 116 (10%) 2.21** 1.42–3.44
Depressive symptoms
Yes 160 (13%) 267 (22%) 1.84** 1.39–2.44
Anxiety
Yes 217 (18%) 255 (21%) 0.93 0.71–1.24
Physical functioning,M (SD) 83.7 (18.1) 77.9 (21.4) 0.94 0.87–1.00
Role functioning, M (SD) 83.6 (24.6) 78.2 (28.1) 0.96 0.92–1.01
Emotional functioning, M
(SD)
87.5 (17.9) 84.9 (20.4) 0.98 0.92–1.05
Social functioning, M (SD) 87.9 (20.5) 86.2 (23.1) 1.05 0.99–1.11
Cognitive functioning, M
(SD)
86.2 (19.8) 84.1 (20.7) 1.01 0.96–1.07
Note: 285 observations were deleted due to missing values. Odds ratios for age and all EORTC functioning scales are expressed per 10-unit increase.
Means (M) with standard deviations (SD) were used to describe normally distributed continuous variables and frequencies with percentages were used to
describe categorical variables. Significant odds ratios are in italics
*p < 0.05; **p < 0.01
aDropouts at any wave, excluding participants who dropped out due to death
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T1 T2 T3 T5
Full response (n=1246) 87.9 88 87.7 87.4
Dropout T3/T4 (n=313) 86.5 86.1 84.3
Dropout T2 (n=219) 83.9 82.9


















T1 T2 T3 T5
Full response (n=1246) 79.8 79.1 79.2 78
Dropout T3/T4 (n=313) 77.7 75.2 73.1
Dropout T2 (n=219) 74.9 70.4
























T1 T2 T3 T5
Full response (n=1246) 83.7 83.7 82.7 81.6
Dropout T3/T4 (n=313) 80.5 79.4 76.6
Dropout T2 (n=219) 76.7 74.4

















** ** ** T1 T2 T3 T5
Full response (n=1246) 83.6 83.9 82.9 82.6
Dropout T3/T4 (n=313) 81.2 80.4 77.2
Dropout T2 (n=219) 74.4 73.5




























T1 T2 T3 T5
Full response (n=1246) 87.9 89 89.3 88.7
Dropout T3/T4 (n=313) 86 87 83.1
Dropout T2 (n=219) 84.2 82.5
















** ** ** T1 T2 T3 T5
Full response (n=1398) 87.5 88.2 88 88.1
Dropout T3/T4 (n=153) 86 85 84.2
Dropout T2 (n=222) 84.2 84.1



























T1 T2 T3 T5
Full response (n=1246) 86.2 86.7 86.1 86.4
Dropout T3/T4 (n=313) 83.3 82.5 82.3
Dropout T2 (n=219) 83.5 81.8
















** ** ** T1 T2 T3 T5
Full response (n=1246) 18.9 19.1 19.5 20.7
Dropout T3/T4 (n=313) 20.7 22.2 23.5
Dropout T2 (n=219) 26.3 28.5





















Fig. 2 Unadjustedmean functioning scores on the EORTCQLQ-C30 (a–
h) and anxiety and depressive symptoms on the HADS (i, j) according to
time of dropout (range: 0–100 and 0–21, respectively). Note: EORTC
QLQ-C30 scales range from 0 to 100; higher scores reflect better
perceived HRQOL. HADS scales range from 0 to 21; higher scores
reflect higher prevalence of anxiety and depressive symptoms. p values
indicate significant group differences between slopes and baseline scores
compared with full responders in multilevel mixed models adjusted for
time, age, sex, socioeconomic status, education, marital status,
comorbidity, disease stage, and treatment received
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Participants who dropped out reported higher prevalence
of depressive symptoms, which increased more steeply over
time, compared with full responders. Epidemiologic studies
have found underestimation of psychiatric disorders due to
non-participation [31, 43] although the relationship between
anxiety, depression, and research participation among cancer
survivors is understudied. Depression frequently appears to be
associated with reduced physical functioning and cancer-related
symptoms including fatigue and pain [44, 45]; all of which may
limit a person’s willingness or capacity to participate in research.
Our results demonstrate that participants who drop out of
PROFILES have significantly lower (statistically and clinical-
ly) HRQOL than those who participate until the final assess-
ment. Independent of mortality, first wave dropouts reported
worse HRQOL at baseline than full responders, which could
be explained by cancer or other illness hindering study partic-
ipation. Given the recent finding that PROFILES participants
survive longer than non-participants [12], our results reinforce
that cancer survivors with the poorest health are likely to be
underrepresented in population-based research. The problem
of selection bias in PRO research has been highlighted in
studies of ovarian and head and neck cancer patients under-
going or up to 1 year post-treatment [2, 13, 46], where partic-
ipants with the lowest baseline HRQOL were more likely to
drop out. After separating participants with attrition due to
death, one study observed fewer group differences at baseline
after adjustment for sociodemographic and clinical factors
[47].With 5-year follow-up and a large population-based sam-
ple allowing subgroup analysis, our study builds upon this
work, providing longer-term insight into the impact of attrition
on HRQOL estimates. Since dropout may be an indicator of
poorer health as well as withdrawal from other activities, ac-
cess to PROFILES participation data could help clinicians
identify patients at risk and refer them to clinical interventions.
It is likely that participation was influenced by factors be-
yond those measured. Participation in population-based re-
search is in decline, possibly owing to increased requests to
participate in research, heightened demands and complexity
of research procedures, and a general decrease in volunteerism
[29]. Characteristics of longitudinal studies with high retention
include individually tailored retention strategies, iterative adap-
tation and refinement of retention processes, and innovative and
persistent research teams [48]. Our results suggest that efforts to
address representativeness and retention in PROFILES might
best be directed towards recruitment and the first follow-up. To
increase participation, PROFILES has recently implemented
phone calls to consenting patients to explain the study. This
strategy appears to have improved the initial response rate,
but it is unknown whether it will help to minimize attrition.
Formal evaluation of this approach is recommended.
To our knowledge, no studies have explored the impact of
attrition on HRQOL in cancer survivors using a longitudinal
and population-based cohort of this size. Study merits include
the sampling frame and availabil i ty of objective
sociodemographic and clinical data on participants and non-
participants. Limitations include the lack of data on reasons
for non-response, which could facilitate a better understanding
of attrition in this population. Data on participant’s racial and
ethnic backgrounds were also lacking. Given that individuals
from racial minorities are underrepresented in research [49] and
less likely to participate in palliative oncology trials [9], this
information should be considered. Because clinical data from
the NCR was only available at diagnosis, a lack of information
about recurrence and disease progression was another limita-
tion. Finally, because all participants were colorectal cancer
survivors, the results cannot be generalized beyond this group.
Due to differences in the timing and methods of data collection
between different PROFILES cohorts, we elected to focus this
investigation on one sample. Examining whether patterns of at-
trition vary between cohorts of cancer survivors participating in
PROFILES is an avenue for future investigation.
The study findings suggest that further investigation of sta-
tistical methods to adjust for non-response and attrition in lon-
gitudinal HRQOL studies is warranted. Transparent reporting of
participation and justification for how missing data were han-
dled in future studies will facilitate interpretation. Although
T1 T2 T3 T5
Full response (n=1246) 4.3 4.3 4.1 4.4
Dropout T3/T4 (n=313) 4.7 4.8 4.8
Dropout T2 (n=219) 5.1 5.5





















** ** ** T1 T2 T3 T5
Full response (n=1246) 3.7 4 4.1 4.6
Dropout T3/T4 (n=313) 4.4 4.8 5
Dropout T2 (n=219) 4.8 5.6
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attrition is not fully preventable, strategies designed to retain
participants [48, 50] particularly those at higher risk of attrition
could improve representativeness. Financial incentives have
been repeatedly associated with higher participant retention in
population-based cohort studies [51] and retention rates have
been found to increase with the value of monetary incentive
offered [50, 51]. Tailored strategies including regular newsletters
and personalized reminders, non-financial incentives, educa-
tional discussion forums, and annual events have been success-
fully implemented in longitudinal cohort studies with high re-
tention rates [48]. It is hypothesised that these approaches may
promote participant engagement, reinforce study benefits and
identity, strengthen staff-participant relationships, and foster a
sense of community, although rigorous evaluation of their
(cost-)effectiveness is lacking [48]. Evidence suggests that re-
tention rates increase with the number of strategies used [50]
and therefore using a combination of methods appropriate to the
study population and context is recommended.
Our findings support and expand upon other longitudinal
studies in oncology showing a selection bias, whereby loss of
participants due to death or illness during follow-up produces
overestimates of HRQOL [13, 46, 47]. Cancer survivors with
the poorest health are at the highest risk of dropping out of
PROFILES and therefore of withdrawing from other activities
too, including those that may benefit well-being. Thus, opti-
mizing participation in PROFILES—a potential mechanism
for providing information and access to support—is an avenue
for keeping this at-risk group engaged. Understanding the
biasing effects of selective attrition on PRO will help to con-
textualize findings from PROFILES and inform strategies for
recruitment, retention, and analysis in population-based
research.
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